Transcatheter mitral valve replacement for degenerated mitral valve bioprostheses, failure of mitral valvuloplasty and native valve with severe mitral annulus calcification: a systematic review and meta-analysis
| Autor: | Yu-Hu Ma, Shao-E He, Xin Zhang, Jie Gao, Tao You, Kang Yi, Wei Wang, Xin-Yao Li, Xiao-Min Xu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Cardiac Catheterization Mitral Valve Annuloplasty Valve-in-MAC RD1-811 medicine.medical_treatment TMVR Ventricular outflow tract obstruction Prosthesis Design Anesthesiology Mitral valve Internal medicine Medicine Humans RD78.3-87.3 Stroke Valve-in-ring Bioprosthesis Heart Valve Prosthesis Implantation business.industry Mitral valve replacement Mitral Valve Insufficiency General Medicine medicine.disease Cardiac surgery Meta-analysis medicine.anatomical_structure Treatment Outcome Cardiothoracic surgery Heart Valve Prosthesis Cardiology Systematic review Valve-in-valve Surgery medicine.symptom Cardiology and Cardiovascular Medicine business Mitral annulus calcification Research Article |
| Zdroj: | Journal of Cardiothoracic Surgery, Vol 16, Iss 1, Pp 1-17 (2021) Journal of Cardiothoracic Surgery |
| ISSN: | 1749-8090 |
| Popis: | Background Although transcatheter technology has achieved some success in the field of mitral valves, the feasibility of applying it to patients with degenerated mitral valve bioprostheses (valve-in-valve, ViV), failure of mitral valvuloplasty (valve-in-ring, ViR) and serious mitral annulus calcification (vale-in-MAC, ViMAC) has not been effectively evaluated. Methods By searching published literature before December 5, 2020 in four databases, we found all the literature related to the evaluation of feasibility assessment of TMViV, TMViR and TMViMAC. Outcomes focused on all-cause mortality within 30 days, bleeding and LVOT obstruction. Results A total of six studies were included, and all of them were followed up for at least 30 days. After analysis of the ViV–ViR group, we obtained the following results: the all-cause mortality within 30 days of the ViV group was lower than that of the ViR group. Life-threatening or fatal bleeding was more likely to occur in the ViR group after surgery. At the same time, the ViR group was more prone to left ventricular outflow tract obstruction. However, in the ViMAC–ViR group, only the all-cause mortality within 30 days and stroke were statistically significant. In the indirect comparison, we found that TMViV had the best applicability, followed by TMViR. There were few TMViMAC available for analysis, and it requires further studies to improve the accuracy of the results. Conclusion TMViV and TMViR had good applicability and could benefit patients who underwent repeat valve surgery. The feasibility of TMViMAC needs to be further explored and improved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|